# Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC

> **NCT03411967** · PHASE2 · UNKNOWN · sponsor: **Zigong No.1 Peoples Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03411967
- **Lead sponsor:** Zigong No.1 Peoples Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03411967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03411967, "Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03411967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*